RESUMEN
Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository "symptom checkers" for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.
Asunto(s)
Tamizaje Neonatal , Enfermedades Raras , Recién Nacido , Humanos , Niño , Tamizaje Neonatal/métodos , Enfermedades Raras/diagnóstico , Enfermedades Raras/epidemiología , Enfermedades Raras/genética , Inteligencia Artificial , Tecnología Digital , Europa (Continente)RESUMEN
The elimination of unfit cells from a tissue is a process known in Drosophila and mammals as cell competition. In a well-studied paradigm "loser" cells that are heterozygous mutant for a haploinsufficient ribosomal protein gene are eliminated from developing tissues via apoptosis when surrounded by fitter wild-type cells, referred to as "winner" cells. However, the mechanisms underlying the induction of this phenomenon are not fully understood. Here we report that a CCAAT-Enhancer-Binding Protein (C/EBP), Xrp1, which is known to help maintaining genomic stability after genotoxic stress, is necessary for the elimination of loser clones in cell competition. In loser cells, Xrp1 is transcriptionally upregulated by an autoregulatory loop and is able to trigger apoptosis - driving cell elimination. We further show that Xrp1 acts in the nucleus to regulate the transcription of several genes that have been previously involved in cell competition. We therefore speculate that Xrp1 might play a fundamental role as a molecular caretaker of the genomic integrity of tissues.
Asunto(s)
Comunicación Celular/genética , Proteínas de Unión al ADN/genética , Proteínas de Drosophila/genética , Factores de Transcripción/genética , Animales , Apoptosis/genética , Proteínas Potenciadoras de Unión a CCAAT/genética , Drosophila melanogaster/genética , Regulación de la Expresión Génica/genética , Ribosomas/genética , Transcripción Genética/genética , Activación Transcripcional/genética , Regulación hacia Arriba/genéticaRESUMEN
Cell competition is a process by which otherwise viable cells are actively eliminated due to the presence of more competitive cells. It is a conserved phenomenon and occurs in various developmental and experimental contexts. Competitive elimination represents a safeguard mechanism that potentiates animal development. However, the process can also be hijacked, for example, by cancer cells to promote and sustain malignancy. One of the challenges facing the field is that the term "cell competition" is used to describe a variety of phenomena whose relatedness is under debate. The goals of this review are to provide an overview of the literature on cell competition-like phenomena, highlight where there are discrepancies, and, when possible, provide alternative interpretations to reconcile the dissonance. Central to this is a comparison of the various models of cell competition. With our critical examination we seek to draw attention to future prospects in the field of cell competition. We believe that the elucidation of the interplay between loser and winner cells in the process of cell competition will provide new targets for the development of cancer therapeutics.
